{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:57:35Z","timestamp":1775091455267,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s11926-019-0830-0","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T07:03:30Z","timestamp":1559804610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis"],"prefix":"10.1007","volume":"21","author":[{"given":"Philip","family":"Mease","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"issue":"4","key":"830_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"830_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/MAJ.0b013e318294457f","volume":"345","author":"JD Reveille","year":"2013","unstructured":"\u2022\u2022 Reveille JD, Weisman MH. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. Am J Med Sci. 2013;345(6):431\u20136 Landmark paper describing the NHANEs epidemiologic survey in the USA, characterizing the prevalence of AxSpA in up to 1.4% of the population, and radiographic AxSpA or AS in approximately 0.5%, with detailed characterization by ethnicity, age, and gender.","journal-title":"Am J Med Sci"},{"key":"830_CR3","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/art.1780341003","volume":"34","author":"M Dougados","year":"1991","unstructured":"Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34:1218\u201327.","journal-title":"Arthritis Rheum"},{"key":"830_CR4","first-page":"85","volume":"57","author":"B Amor","year":"1990","unstructured":"Amor B, Dougados M, Mijiyawa M. Criteria for the classification of spondyloarthropathies. Rev Rheum Mal Osteoaric. 1990;57:85\u20139.","journal-title":"Rev Rheum Mal Osteoaric"},{"issue":"6","key":"830_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.108217","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Landewe R, van der Heijde D, et al. The development of Assessment of Spondylo Arthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68(6):770\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"830_CR6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"\u2022 Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of Spondylo Arthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383 These two papers describe the axial spondyloarthritis classification criteria\u2014the study design and conduct of the study upon which the criteria is based and the final criteria.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"830_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"\u2022 Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of Spondylo Arthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25\u201331 These two papers describe the axial spondyloarthritis classification criteria\u2014the study design and conduct of the study upon which the criteria is based and the final criteria.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"830_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"\u2022 van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391 This paper summarizes the most recent ASAS-EULAR treatment recommendations for AxSpA.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"830_CR9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"\u2022 Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic Axial spondyloarthritis. Arthritis Rheum. 2016;68(2):282\u201398 This paper summarizes the ACR-SAA-SPARTAN treatment recommendations for AxSpA.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"830_CR10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","volume":"75","author":"T Dorner","year":"2016","unstructured":"Dorner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75(6):974\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"830_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1056\/NEJMra0707449","volume":"361","author":"P Miossec","year":"2009","unstructured":"Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888\u201398.","journal-title":"N Engl J Med"},{"issue":"2","key":"830_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/BOR.0000000000000147","volume":"27","author":"PJ Mease","year":"2015","unstructured":"\u2022\u2022 Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015;27(2):127\u201333 This paper reviews the IL-17\/IL-23\/TH17 cell pathway which is of critical importance in the pathophysiology of AxSpA, psoriasis, and psoriatic arthritis.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"830_CR13","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3370","volume":"13","author":"H Appel","year":"2011","unstructured":"Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011;13(3):R95.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"830_CR14","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","volume":"60","author":"H Shen","year":"2009","unstructured":"Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60(6):1647\u201356.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"830_CR15","doi-asserted-by":"publisher","first-page":"e31000","DOI":"10.1371\/journal.pone.0031000","volume":"7","author":"L Zhang","year":"2012","unstructured":"Zhang L, Li YG, Li YH, et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One. 2012;7(4):e31000.","journal-title":"PLoS One"},{"issue":"4","key":"830_CR16","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.4049\/jimmunol.1002653","volume":"186","author":"P Bowness","year":"2011","unstructured":"Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011;186(4):2672\u201380.","journal-title":"J Immunol"},{"issue":"7","key":"830_CR17","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"\u2022\u2022 Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3\u2009+\u2009CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069\u201376 Seminal paper, using a murine model, for the hypothesis that a key pathway in the pathogenesis of spondyloarthritides is through the stimulation of resident lymphocytes by IL-23 which in turn produce IL-17, IL-22, and TNF which interact with effector cells in various sites to create the osteolytic and osteoproliferative pathology of these conditions.","journal-title":"Nat Med"},{"issue":"10","key":"830_CR18","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/art.39732","volume":"68","author":"A Reinhardt","year":"2016","unstructured":"Reinhardt A, Yevsa T, Worbs T, et al. Interleukin-23-dependent gamma\/delta T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice. Arthritis Rheum. 2016;68(10):2476\u201386.","journal-title":"Arthritis Rheum"},{"issue":"26","key":"830_CR19","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"\u2022 Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348 Paper describing the pivotal trials leading to the approval of secukinumab, an IL-17i, in ankylosing spondylitis.","journal-title":"N Engl J Med"},{"issue":"10163","key":"830_CR20","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"\u2022 van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16\u00a0week results of a phase 3 randomized, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441\u201351 Paper describing a pivotal trial of ixekizumab, an IL-17i, in AS\/radiographic AxSpA (r-AxSpA) patients na\u00efve to biologic therapy.","journal-title":"Lancet."},{"key":"830_CR21","unstructured":"\u2022 Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: 16\u00a0week results of a phase 3 randomized, double-blind, placebo controlled trial in patients with prior inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheum. 2018; Paper describing a pivotal trial of ixekizumab, an IL-17i, in AS\/r-AxSpA patients who have previously been treated with TNFi."},{"issue":"7","key":"830_CR22","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/nm.2854","volume":"18","author":"RJ Lories","year":"2012","unstructured":"\u2022\u2022 Lories RJ, McInnes IB. Primed for inflammation: enthesis-resident T cells. Nat Med. 2012;18(7):1018\u20139 Eloquent editorial on the importance of reference 17, the Sherlock paper.","journal-title":"Nat Med"},{"issue":"4","key":"830_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.rdc.2015.07.010","volume":"41","author":"PJ Mease","year":"2015","unstructured":"Mease PJ. Biologic therapy for psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):723\u201338.","journal-title":"Rheum Dis Clin N Am"},{"key":"830_CR24","doi-asserted-by":"crossref","unstructured":"Kaushik SB, Lebwohl MG. Review of safety and efficacy of approved systemic psoriasis therapies. Int J Dermatol. 2018.","DOI":"10.1111\/ijd.14246"},{"issue":"5","key":"830_CR25","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817\u201323.","journal-title":"Ann Rheum Dis"},{"key":"830_CR26","doi-asserted-by":"crossref","unstructured":"Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheum. 2018.","DOI":"10.1002\/art.40728"},{"key":"830_CR27","doi-asserted-by":"crossref","unstructured":"Mease PJ, Kellner H, Morita A, et al. Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. Arthritis Rheum. 2017;69(suppl 10).","DOI":"10.1136\/annrheumdis-2018-eular.2140"},{"issue":"10148","key":"830_CR28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650\u201361.","journal-title":"Lancet."},{"issue":"9","key":"830_CR29","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, Ostergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295\u2013302.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"830_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/art.40759","volume":"71","author":"P Mease","year":"2019","unstructured":"\u2022 Mease P. Ustekinumab fails to show efficacy in a phase III axial spondyloarthritis program: the importance of negative results. Arthritis Rheum. 2019;71(2):179\u201381 Editorial hypothesizing why two medications which inhibit IL-23, ustekinumab and risankizumab, may have failed to show efficacy in the treatment of ankylosing spondylitis.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"830_CR31","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","volume":"72","author":"E Pathan","year":"2013","unstructured":"Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013;72(9):1475\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"830_CR32","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"\u2022 van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340\u20137 Pivotal studies demonstrating the effectiveness of two JAK inhibitors, tofacitinib, and filgotinib in the treatment of ankylosing spondylitis.","journal-title":"Ann Rheum Dis"},{"issue":"10162","key":"830_CR33","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"\u2022\u2022 van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2378\u201387 Pivotal studies demonstrating the effectiveness of two JAK inhibitors, tofacitinib, and filgotinib in the treatment of ankylosing spondylitis.","journal-title":"Lancet."},{"key":"830_CR34","unstructured":"Smolen J, Breedveld F, Burmester G, et al. Extended report: treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015."},{"issue":"1","key":"830_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6\u201316.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"830_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"\u2022\u2022 Smolen JS, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3\u201317 Synopsis of the systematic literature review and expert discussion on the \u201ctreat-to-target\u201d concept in the management of AxSpA and psoriatic arthritis.","journal-title":"Ann Rheum Dis"},{"issue":"10012","key":"830_CR37","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489\u201398.","journal-title":"Lancet."},{"key":"830_CR38","doi-asserted-by":"crossref","unstructured":"van den Bosch F, Carron P, Mease P. Biologic treatment of axial spondyloarthritis. Chapter 15. In: Mease P, Khan M, editors. Axial spondyloarthritis: Elsevier Inc; 2019. p. 223\u201338.","DOI":"10.1016\/B978-0-323-56800-5.00015-1"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-019-0830-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-019-0830-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-019-0830-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T06:58:44Z","timestamp":1694933924000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-019-0830-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,6]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1007\/s11926-019-0830-0","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,6]]},"assertion":[{"value":"6 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Mease reports grants and personal fees from AbbVie, grants and personal fees from Amgen, grants and personal fees from Bristol Myers Squibb, personal fees from Boehringer Ingelheim, grants and personal fees from Celgene, personal fees from Galapagos, personal fees from Genentech, personal fees from Gilead, grants and personal fees from Janssen, grants and personal fees from Lilly, grants and personal fees from Novartis, grants and personal fees from Pfizer, grants and personal fees from Sun, grants and personal fees from UCB, during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"35"}}